EDITAS MEDICINE, INC. Net Fee Amt
EDITAS MEDICINE, INC. (EDIT) had Net Fee Amt of $397.52 as of 2026-09-09, per its S-8 filed 2026-09-09.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-09
- 2026-09-09: Net Fee Amt $397.52.
- 2026-08-28: Net Fee Amt $55.24K.
- 2026-05-26: Net Fee Amt $1.85K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-09 | $397.52 S-8 · filed 2026-09-09 |
| 2026-08-28 | $55.24K S-3 · filed 2026-08-31 |
| 2026-05-26 | $1.85K S-3MEF · filed 2026-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |